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Summary
Kinase inhibitors that bind to the ATP cleft can be
broadly classified into two groups: those that bind ex-
clusively to the ATP site with the kinase assuming
a conformation otherwise conducive to phosphotrans-
fer (type I), and those that exploit a hydrophobic site im-
mediately adjacent to the ATP pocket made accessible
by a conformational rearrangement of the activation
loop (type II). To date, all type II inhibitors were discov-
ered by using structure-activity-guided optimization
strategies. Here, we describe a general pharmacophore
model of type II inhibition that enables a rational
‘‘hybrid-design’’ approach whereby a 3-trifluorome-
thylbenzamide functionality is appended to four dis-
tinct type I scaffolds in order to convert them into their
corresponding type II counterparts. We demonstrate
that the designed compounds function as type II inhib-
itors by using biochemical and cellular kinase assays
and by cocrystallography with Abl.
Introduction
There are 518 kinases encoded in the human genome,
and they have been demonstrated to play pivotal roles
in virtually all aspects of cellular physiology [1]. Misregu-
lation of kinase activity has been implicated in patholog-
ical conditions ranging from cellular transformation in
leukemias to neuronal disorders. Hyperactivated ki-
nases that are no longer subject to normal physiological
constraints result from activating point mutations, for-
*Correspondence: yliu@gnf.org (Y.L.); nathanael_gray@dfci.harvard.
edu (N.S.G.)
4 These authors contributed equally to this work.mation of constitutively active fusion proteins, loss
of negative regulators, and excessive stimulation by
extracellular growth factors [2–5]. New classes of selec-
tive kinase inhibitors are urgently needed as ‘‘tools’’ to
decipher the biological function of the large number of
still uncharacterized kinases and as starting points for
the development of drugs targeting therapeutically rele-
vant kinases.
The highly conserved kinase domain consists of a bi-
lobed structure, with Mg-ATP binding in a deep cleft lo-
cated between the two lobes. The vast majority of small-
molecule kinase inhibitors developed to date target the
ATP binding site (type I inhibitors), with the kinase as-
suming a conformation almost identical to that used to
bind ATP. Typically, type I inhibitors form between one
and three hydrogen bonds to the backbone hinge amino
acid residues that connect the N- and C-terminal lobes
of the kinase domain [6]. Although some highly selective
members of this class have been discovered, the highly
conserved nature of the ATP binding region often results
in type I inhibitors exhibiting poor kinase selectivity. The
majority of type I inhibitors have been derived from leads
discovered by using biochemical kinase assays per-
formed at low ATP concentrations. These conditions fa-
vor the discovery of hydrophobic compounds that bind
to the nucleotide binding pocket.
Fortunately, serendipity allowed for the identification
of a second broad class of kinase inhibitors that prefera-
bly inhibits the inactive conformation of the kinase,
thereby preventing its activation (Figure 1). This inactive
conformation was first observed crystallographically in
an inactive conformation of an unliganded insulin recep-
tor kinase [7], but it was not until the structures of Abl
in complex with imatinib and analogs were solved that
it became clear that this conformation could be exploited
by inhibitors [8–10]. This second broad class of kinase in-
hibitors (type II) utilizes the ATP binding cleft and an im-
mediately adjacent hydrophobic pocket that is created
when the activation loop, which contains the conserved
DFG motif, is in an out conformation. The resulting DFG-
out conformation is termed the ‘‘inactive conformation’’
because the amino acids in the ATP pocket are not ori-
ented in a manner that would allow phosphotransfer to
be catalyzed and the activation loop is in a conformation
that blocks the approach of ATP and the substrate. Sev-
eral distinct inhibitors, such as imatinib [9], BIRB796 [11],
sorafenib [12], AAL993 [13], and others [14–16], have
been crystallographically proven to be type II inhibitors.
A third broad class of kinase inhibitors that modulate
kinase activity by binding at sites remote from the ATP
cleft can be recognized. To date, only a few compounds
have been disclosed that operate by this mechanism:
the MEK inhibitors PD098059, PD184352, and U0126
[17–19]; the glucose kinase activator TDZD [20]; the IKK
inhibitor BMS345541 [21]; the non-ATP-competitive Abl
inhibitor GNF-2 [22]; the plekstrin homology domain-
dependent Akt inhibitors Akt-I-1,2 [23]; and the Plk inhib-
itor ON01910 [24].
Here, we describe a simple chemical strategy for con-
verting four known type I inhibitors into corresponding
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780Figure 1. Recognizing ‘‘Type II’’ Inhibitors
(A–D) Chemical structures of imatinib
(ST1571), BIRB796, sorafenib (BAY43-9006),
and AAL993 highlighting the conserved hy-
drogen bond accepting (red circles) and do-
nating (blue circles) interactions inferred by
crystallography.
(E) Imatinib (gold) bound to Abl (yellow
ribbon).
(F) Overlapping view of imatinib (gold) and
sorafenib (blue) showing the molecular
mimicry of the two.
(G) Pharmacophore model of a type II
inhibitor.
A, D = hydrogen bond acceptor, donor;
HRB = hinge region binder; HM1, 2 = hydro-
phobic motif 1, 2.type II inhibitors with different kinase selectivity profiles
and exceptionally potent cellular activity.
Results
In order to develop a general pharmacophore model for
type II kinase inhibitors, we searched for structural
features conserved in all known type II inhibitor kinase
costructures. This analysis revealed that the majority
of type II inhibitors made two pairs of conserved hydro-
gen bonds to their respective kinase targets: one pair to
the hinge region amino acid and a second pair to the
side chain carboxylate of a conserved glutamate in the
a-C helix and to the backbone NH of the aspartate lo-
cated in the DFG motif [8, 10]. In addition, all of the inhib-
itors had a hydrophobic substitution that occupied the
region normally utilized by the phenyl ring of the phenyl-
alanine of the DFG motif in the active conformation. The
cocrystal structures revealed that despite the distinct
chemical structures of the type II inhibitors, the distance
between the hydrogen bond donor and acceptor func-
tionality is highly conserved (Table 1). These observa-
tions can be combined to create a general pharmaco-
phore model for a type II kinase inhibitor (Figure 1).
Inhibitor Design Strategy
We hypothesized that we could convert known type I in-
hibitors into type II inhibitors by appending a second hy-
drogen bonding pair and hydrophobic motif onto a type I
scaffold. To test this hypothesis, we selected four type I
inhibitors from distinct scaffold classes (1, 4, 7, and 11)
and introduced a 3-trifluoromethylbenzamide substitu-
ent at a position that molecular modeling predicts would
mimic the placement of the same moiety in sorafenib
(BAY43-9006) to generate four classes of potential
type II inhibitor scaffolds (2, 5, 8, 9, 12, and 14; Figure 2).
The four type I scaffolds were chosen because of their
high structural similarity to compounds whose bindingmode to kinases has been determined by X-ray crystal-
lography or on the basis of molecular modeling, which
allowed us to predict the optimal attachment site for
the 3-trifluoromethylbenzamide. For example, com-
pound 1 was derived from the phenylamino pyrimidine
class [25], which were the lead structures for the devel-
opment of the known type II inhibitor imatinib, and it is
expected to form a hydrogen bond from pyridine nitro-
gen to the kinase hinge (cocrystal of Gleevec with
c-Abl; PDB code: 1IEP). Alternatively, based on the
closely related CDK inhibitors (cocrystal of human
CDK2 with various small-molecule inhibitors; PDB codes:
1PXM, 1PXN, 1PXO, and 1PXP) [26], compound 1 could
also form a pair of hydrogen bonds from the pyrimidine
N1 and 2-NH to the kinase hinge region. The second
scaffold, 4, was designed as a simplified version of the
pyrrolopyrimidine Jak-3 inhibitor CP690550 [27], and it
is expected to form a pair of hydrogen bonds from N1
and the 9-NH to the kinase hinge (cocrystal of B-Raf
with BAY43-9006; PDB code: 1UWH). The tricyclic inhib-
itor 7 was designed based on the structurally related p38
MAP kinase inhibitor [28], and it is expected to bind to
the kinase hinge by using the same functionality as
compound 4. Pyrido[2,3-d]pyrimidine compound 11 is
an example of a well-characterized dual Src/Abl inhibi-
tor that has been recently shown to inhibit a subset of
Table 1. Distance and Bond Number between the H Bond
Acceptor in the Hinge Region and the Second H Bond Acceptor in
the DFG Motif of Four Known Type II Inhibitors
Inhibitor
Distance between
Hinge Acceptor and
DGF-Motif Acceptor (A˚)
Number of Bonds between
Hinge Acceptor and
DGF-Motif Acceptor
Imatinib 10.0 12
BIRB796 9.7 12
Sorafenib 8.8 11
AAL993 7.3 9
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781imatinib-resistant Bcr-Abl mutants (cocrystal of c-Abl
with PD173955; PDB code: 1M52) [29, 30]. We use four
lines of evidence to suggest that the type II inhibitors
bearing 3-trifluoromethylbenzamide bind to kinases dif-
ferently than their progenitor type I scaffolds. First, the
3-trifluoromethylbenzamide-containing structures dis-
play significantly altered kinase selectivity in enzymatic
and cellular assays. Second, for the compounds with
activity against Abl kinase, we demonstrate that the
type II inhibitors show a trend toward greater potency
against dephosphorylated versus phosphorylated Abl.
Third, we demonstrate the importance of the hydrogen
bond-donating group formed by the amide (or urea) for
obtaining potent kinase inhibition. Fourth, we have ob-
tained a cocrystal of compound 14 with the catalytic
domain of Abl, which demonstrates that it binds to the
enzyme with an activation loop in the ‘‘DFG-out’’ confor-
mation (type II mode).
Biochemical Kinase Selectivity
All of the compounds were tested against a panel of 59
recombinant serine/threonine and tyrosine kinases at
a concentration of 1 or 10 mM (Figure 3). As illustrated
in Figure 3, all of the type I and II inhibitor pairs (1 versus
2, 4 versus 5, 7 versus 8, and 11 versus 12) exhibit signif-
icant differences in kinase selectivity. Three of the type I
inhibitors exhibit only weak inhibitory activity (IC50 >
1 mM) on a limited number of kinases in the panel: 1 on
c-Kit, Fms, KDR, Aurora A, Gsk3b, and Tie2; 4 on Jak2
and FGFR3; 7 on Jak2 and Tie2. Consistent with a close
analog reported in the literature [29], the fourth type I
Figure 2. Chemical Structures of Four Classes of Designed Type II
Inhibitors and Their Respective Type I Progenitors
Presumed hydrogen bonds are shown as dashed lines.inhibitor, 11, exhibited potent pan-tyrosine kinase inhib-
itory activity as well as activity against serine/threonine
kinases such as c-Raf, MAPK1, Aurora A, Jak 2&3, Nlk,
and c-Met. In contrast, each type II inhibitor exhibited
significantly altered selectivity. For example, 2, which
has a structure highly similar to imatinib and nilotinib,
exhibited enzymatic inhibitory activity against Abl, Blk,
Brk, c-Kit, c-Src, Lck, PDGFR-a, c-Raf, Fms, Fyn, TrkB,
and Sapk2a. The type II inhibitor, 5, which is structurally
similar to sorafenib, exhibited a very broad biochemical
inhibitory profile inhibiting Alk, Aurora A, Flt3, Jak2, Fyn,
Ron, p70S6K, and Ros kinases in addition to the kinases
targeted by the phenylaminopyrimidine 2. The type II in-
hibitor 8 also was more potent and displayed a broader
kinase selectivity than its progenitor 7. It was also capa-
ble of inhibiting c-Raf, Abl, Aurora A, Lck, Fms, PDGFR-
a, KDR, Sapk2a, TrkB, Jak2, and, to a lesser, extent
c-Kit, MAPK1, and Tie2. The fourth type II inhibitor, 12,
also exhibited altered selectivity relative to its progeni-
tor, 11, albeit to a lesser extent than the previous three
compound pairs due to the already poor selectivity of
11. These dramatic alterations in both selectivity and
potency would suggest that each pair recognizes the
kinase active site through fundamentally different bind-
ing modes. Although three of the newly created type II
inhibitors (2, 5, and 8) inhibited more kinases than their
type I counterparts (1, 4, and 7), we discovered that
small alterations could be made to the type II inhibitors
to create highly selective inhibitors. This is exemplified
by the replacement of the urea of 5 with an amide in 6,
which resulted in a dramatic improvement in selectivity;
6 only significantly inhibited Flt3, Fms, PDGFR-a, KDR,
and TrkB. These results suggest that the type II inhibi-
tors 2, 5, 6, 8, and 12 can be viewed as core scaffolds
that can be further elaborated to obtain inhibitors with
the desired spectrum of inhibitory activities.
Cellular Kinase Selectivity
As there are frequently discrepancies observed be-
tween kinase inhibition measured by using biochemical
versus cellular kinase assays, we evaluated the inhibi-
tors in kinase-dependent cellular proliferation assays
[31]. We utilized a cellular system in which murine Ba/
F3 cells are transformed with 30 different constititutively
active Tel-tyrosine kinase fusions to render them capa-
ble of growth in the absence of cytokine (IL-3) [31]. Se-
lective kinase inhibition results in a blockade of cellular
proliferation that can be discriminated from nonspecific
cytotoxicity by comparison to inhibition of untrans-
formed Ba/F3 cells or by reversal of compound-induced
inhibition with cytokine (IL-3). As expected from the bio-
chemical assays, three of the type I inhibitors (1, 4, and 7)
exhibited no cellular activity on any of the kinases at a
concentration below 1 mM; however, compounds 1 and
7 exhibited some activity below 5 mM (1: KitQ = 2.0 mM;
7: Ros = 1.6 mM). In agreement with published data
of a close analog, the pyridopyrimidinone 11 exhibited
potent inhibition of Bcr-Abl (IC50 = 4 nM), Flt3 (IC50 =
1791 nM), and PDGFR-b (IC50 = 100 nM). In stark con-
trast, the corresponding type II analog, 12, exhibited
potent inhibition across the entire panel, which may re-
sult in part from cytotoxicity to parental Ba/F3 cells
(IC50 = 300 nM). However, all other putative type II inhib-
itors displayed very potent cellular activities as
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Compounds 1–11, 13, and 14 were assayed at 1 mM, and compound 12 was assayed at 10 mM. Color gradation is proportional to the percent-
age of activity remaining: Green = inhibited; red = not inhibited.visualized in Figure 4 (IC50 values are reported in the
Supplemental Data available with this article online,
see Table S1). For example, inhibitors 2, 5, 8, 12, and
14 all displayed sub-100 nM activity against cellular
PDGFR-b, while 2, 8, 12, and 14 targeted Bcr-Abl with
IC50s in the 3–110 nM range. Type II inhibitor 6 displayed
a unique and selective inhibitory profile of Flt3, c-Kit,
and PDGFR-a/b. Another notable change in the selectiv-
ity profile is demonstrated by the replacement of
2-methyl substituent of 8 with a 3-methoxy group of 9
that possesses a sub-100 nM cellular IC50 exclusively
against c-Kit. The two-dimensional hierarchical cluster-
ing also reveals that the 3-trifluoromethylbenzamide
‘‘tail’’ portion of these inhibitors exhibited a dominant
effect on the overall kinase selectivity. This is demon-
strated by the proximal clustering of 2 and 8 and 3 and
6, where the hinge region interacting motifs are structur-
ally quite different. The results show that the designed
type II inhibitors can potently inhibit the cellular activity
of different subsets of tyrosine kinases.
SAR for Amide and Urea Modifications
To investigate the importance of the amide (or urea for 5)
NH to serve as a hydrogen bond donor, the correspond-
ing N-methyl (3, 10, 13, and 15) or CH2 (6) replacements
were prepared and tested for cellular kinase inhibition.
As expected from the design strategy, both compounds
3 and 10 exhibited approximately a 100-fold loss in cel-lular activity on Bcr-Abl and PDGFR-b, while 13 lost ac-
tivity on ALK, Bcr-Abl, BMX, EphA3, EphB4, and a host
of other kinases. Interestingly, compound 6 lost activity
on KDR, and there was a decrease in activity on several
other kinases as well. However, activity on PDGFR-b
was maintained potentially due to the ability of the other
urea NH to provide an alternative hydrogen bond donor.
These results show that the urea or amide NH is essen-
tial for potent cellular inhibition of the newly designed
type II inhibitors, and this finding is consistent with the
binding mode predicted by the design strategy.
Biochemical Inhibition of Differentially
Phosphorylated Abl
It has been previously demonstrated that imatinib pos-
sesses a lower IC50 for inhibition of the activation loop-
dephosphorylated Abl than for fully phosphorylated Abl
[8, 9]. This is presumed to result from imatinib’s prefer-
ence for binding to the activation loop-dephosphory-
lated Abl, which can preferentially assume the DFG-out
conformation. In order to determine IC50s against phos-
phorylated (more active) and dephosphorylated (less
active) Abl kinases, we established an in vitro kinase
assay by using either phosphorylated or dephosphory-
lated recombinant human Abl kinase domains to phos-
phorylate a peptide substrate. Using this assay, imatinib
was demonstrated to be w85-fold more potent on
dephosphorylated compared to phosphorylated Abl.
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783Figure 4. Heat Map for Antiproliferative
IC50s, in mM, of Compounds 1–14 on Parental
and Kinase-Transformed Ba/F3 Cells
Gray = not tested.In contrast, the known type I inhibitor PD173955 was
equipotent in both assays (Table 2) [8]. As expected
from the design strategy, the type II compounds 2, 5,
and 8 exhibited several fold lower IC50s for the dephos-
phorylated Abl. In line with our expectations, the control
compounds 3, 6, and 10 were all inactive in the biochem-
ical assay. These results would suggest that compounds
2, 5, and 8 are able to preferentially bind and inhibit the
dephosphorylated inactive Abl conformation compared
with phosphorylated active Abl. In contrast to our expec-
tations, type II analogs 12 and 14 did not exhibit any dif-
ferential in activity with respect to the phosphorylation
state of the Abl enzyme. The exceptional potency of 12
and 14 may be sufficient to drive the conformational
equilibrium in favor of the DFG-out state regardless of
the phosphorylation status of the kinase. Unlike com-
pound 13, N-Me analog 15 showed no activity of Abl in ei-
ther the phosphorylated state or the dephosphorylated
state. This result might be explained by the fact that 13
has an optimized type I inhibitor region; hence, modifica-
tion of amide linkage in the allosteric pocket has a mini-
mal effect on the potency of the molecule.
Crystal Structure of 14 with Abl
In an effort to determine the inhibitor bound conforma-
tion of Abl, we solved the cocrystal structure with a sim-
plified structural analog of compound 12 (14) to a resolu-
tion of 2.3 A˚ (Figure 5). Compound 14 was used instead of
12 because of its enhanced water solubility and similar
biological profile in both biochemical and cellular kinase
assays (Tables 1 and 2; Table S1). The cocrystal struc-
ture revealed that compound 14 indeed utilizes a type II
binding mode to Abl; the activation loop in the DFG-out
conformation is highly reminiscent of Abl bound to ima-
tinib or nilotinib (AMN-107) [32]. Furthermore, the
cocrystal showed all of the expected inhibitor-protein
interactions predicted by the design strategy: a pair of
hydrogen bonds to the kinase hinge (residue Met318)
from the aminopyrimidine motif, a twisted conformation
of the tolyl moiety, two hydrogen bonds from the amide
to the side chain of Glu286 in the a-C helix and to the
backbone amide of D381 in the DFG motif. A superposi-
tion with imatinib revealed the high degree of molecular
mimicry between the two compounds. Based on data
available from kinase cocrystal structures of nilotinib
with Abl (analog of 2), sorafenib with b-Raf (analog of
5), and 14 with Abl, one can see that all compounds
exhibit the conserved features of the type II binding
mode. All costructures exhibit the DFG-out conforma-
tion of the activation loop and two pairs of conservedhydrogen bonds: one pair binds to the hinge region
amino acid, and a second pair binds to the side chain
carboxylate of a conserved glutamate in the a-C helix
and to the backbone NH of the aspartate in the DFG motif
in the allosteric region.
Discussion
There is an ever-increasing demand for new protein
kinase inhibitors both as potential therapeutics and as
tools to aid in dissecting complex signaling pathways.
Despite the tremendous efforts to develop new kinase
inhibitors, the vast majority of kinases are still not tar-
geted by an inhibitor with a reasonable level of selectiv-
ity. Currently, the majority of known small-molecule ki-
nase inhibitors exclusively target the ATP binding site
of the fully activated kinase (type I inhibitors). A second
class of inhibitors (type II inhibitors) that exploit a hydro-
phobic pocket immediately adjacent to the ATP binding
site created by a unique DFG-out conformation of the ac-
tivation loop characteristic of an inactive kinase was
subsequently identified. Because type II inhibitors rec-
ognize regions of the kinase active cleft outside of the
highly conserved ATP binding site, they have been pre-
dicted to have the potential to exhibit a higher degree
of kinase selectivity. To date, all of the known type II in-
hibitors have been identified serendipitously and were
only later determined to be type II binders through exam-
ination of X-ray costructures. By inspecting the inhibitor
bound conformations of all type II inhibitors for which
Table 2. IC50s, in nM, of Type II Inhibitors on Phosphorylated and
Dephosphorylated Abl
Inhibitor Phosphorylated Abl Dephosphorylated Abl
Imatinib >5000 27.0
PD173955 24.0 23.0
1 >5000 >5000
2 152 5
3 >5000 1362
4 >5000 >5000
5 >5000 374
6 >5000 >5000
7 >5000 >5000
8 >5000 154
10 >5000 >5000
11 5.7 5.8
12 19.6 27.2
13 150.1 9.1
14 11.0 8.0
15 >5000 >5000
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Bound to Abl
(A) Chemical structure of compound 14.
(B) H-bonding interactions of compound 14
with Abl ATP site residues.
(C) Superimposition of compound 14 and
soranefib bound to Abl.
(D) Ribbon diagram of Abl kinase in the pres-
ence of imatinib and compound 14.there are known kinase cocrystal structures, we were
able to derive a general pharmacophore model.
This pharmacophore model suggests that grafting a
3-trifluoromethylbenzamide moiety to the appropriate
position on a type I inhibitor would provide a simple
strategy for synthesizing new type II inhibitors. We
exploited this approach to prepare four distinct classes
of type II inhibitors (2, 5, 8, 9, 12, and 14) from known
type I inhibitors (1, 4, 7, and 11). For all four compound
pairs, the type II inhibitors were more capable of inhibit-
ing the enzymatic activity of a larger number of kinases
than their corresponding type I counterparts at concen-
trations of 1 or 10 mM. This is likely to result from a com-
bination of changes in inhibitor potency and selectivity:
type II inhibitors can display lower IC50s for certain
kinases and/or possess the ability to inhibit fundamen-
tally distinct kinases compared to type I inhibitors. The
comparison of kinase selectivity between type I and II in-
hibitors needs to be performed on a larger set of inhibi-
tors before any general conclusion can be drawn. With
the exception of 11, the type I inhibitors used as starting
scaffolds in this work (1, 4, and 7) are not potent kinase
inhibitors; consequently, this makes them appear to be
selective.
In contrast to previously described type II inhibitors,
we have demonstrated that it is possible to make
type II inhibitors such as 12 and 14 that are exceptionally
potent and nonselective kinase inhibitors. This demon-
strates that despite the ability of these inhibitors to ex-
ploit the less-conserved allosteric pocket, their overall
mode of kinase binding can be sufficiently generic
such that the desired kinase selectivity is not achieved.
However, we have also shown that the selectivity of the
type II compounds can be dramatically enhanced by
very subtle chemical alterations, as exemplified by com-
pounds 6 and 9. Similarly, modification in compound
11 led to nonselective type II analog 12 or to a more
selective compound, 14. We demonstrated that for the
compounds with nonoptimized hinge contact for whichBcr-Abl was a target (2, 5, and 8), the type II inhibitors
displayed a significantly lower IC50 against dephos-
phorylated Abl enzyme. This result suggests that the
type II inhibitors are capable of accessing a more pro-
ductive inhibitory conformation when the kinase is de-
phosphorylated, in contrast to type I inhibitors, for which
this discrimination is not apparent. Moreover, the type II
scaffolds are demonstrated to target a spectrum of ki-
nases that can be restricted based on subtle alterations
to the chemical structure, as exemplified by 5 versus 6
and 8 versus 9.
When tested for the inhibition of cell proliferation de-
pendent on a panel of 30 tyrosine kinases, all 4 classes
of type II inhibitors displayed potent cellular activity
against one or more tyrosine kinases. This was in stark
contrast to the four type I inhibitor classes for which
only the pyrimidopyrimidone 11 displayed potent cellu-
lar activity against a large number of tyrosine kinases.
From the cocrystal structures obtained of compound
14 and Abl, we were able to conclusively demonstrate
that this compound does indeed bind to the DFG-out
Abl conformation, as has been observed for imatinib
and nilotinib. The remarkable cellular activity of the
type II inhibitors may result from their binding to the
inactive conformation of the kinases, which may be
more accessible in the cellular environment.
A key challenge to furthering the development of new
type II inhibitors as therapeutic leads is to develop a de-
tailed understanding of how structural modifications im-
pact kinase selectivity. This will require preparing a vari-
ety of structural analogs in order to explore cellular
structure-activity against a panel of kinases. An example
of such a modification is the replacement of the urea NH
of compound 5 with a methylene to form compound 6,
which results in a significant improvement of kinase se-
lectivity. Additional challenges include finding effective
strategies for increasing the solubility and pharmacoki-
netic properties of compounds containing the highly li-
pophilic 3-trifluoromethylbenzamide substituent.
‘‘Inactive-Conformation’’ Abl Kinase Inhibitors
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is likely that the technique we describe here will provide
a simple rational way to construct a large number of
type II inhibitor counterparts that will display distinct ki-
nase selectivity profiles and exceptional cellular potency.
The ability to readily achieve extraordinary cellular po-
tency against a diverse assortment of kinase targets will
likely make this strategy for creating new type II inhibitors
popular for both the development of therapeutic lead
compounds and for making ‘‘tool’’ compounds for phar-
macological interrogation of cellular signaling networks.
Significance
Tremendous effort is being invested in the discovery of
protein kinase inhibitors for the treatment of a number
of human diseases. Although 5 distinct small-molecule
kinase inhibitors have been approved for the treatment
of specific cancers and over 100 agents are under clin-
ical evaluation, the vast majority of kinases are still not
targeted by an inhibitor with a useful level of selectivity
[33]. There is therefore a compelling need to expand the
diversity of small-molecule scaffolds that can be tuned
to the desired selectivity profile. Here, we describe
a simple chemical strategy that can be applied to trans-
form the large number of compounds that are known to
target the ATP binding pocket of active kinases (type I)
[34, 35] into inhibitors that can exploit an additional hy-
drophobic binding site available in the DFG-out confor-
mation (type II). The hybrid-design approach involves
grafting functionality from known type II inhibitors
onto type I scaffolds. By targeting the DFG-out confor-
mation, the resulting type II hybrid compounds can
exhibit exceptional cellular potency and can serve as
starting points for elaboration of compounds with
a range of selectivity profiles that can serve as leads
for drug discovery or as pharmacological probes of
signaling pathways.
Experimental Procedures
Generation of Tyrosine Kinase-Transformed Ba/F3 Cells
Kinase domains (KD) of tyrosine kinases were individually PCR am-
plified from a human cDNA library, subsequently cloned into a mod-
ified pMSCVpuro vector (Clontech), and transduced into Ba/F3 cells
as previously described [31]. Expression of tyrosine kinases in trans-
duced Ba/F3 cells was confirmed by immunodetection of the Tel-KD
fusion proteins and by sequence analysis of RT-PCR products.
Ba/F3 Cell Proliferation Assay
Ba/F3 cells transformed by tyrosine kinases were dispensed into
a 384-well format plate at 5000 cell/well in 50 ml culture medium.
Twelve point serial dilutions of the test compounds in DMSO were
transferred into cell plates to final compound concentration gradi-
ents ranging from 0.05 to 10,000 nM. After incubation at 37C in
5% CO2 for 48 hr, relative cell numbers for each compound treat-
ment were determined by measuring the luminescent signal result-
ing from addition of the luciferase substrate Bright-Glo (Promega).
IC50 values are calculated by linear regression analysis of the per-
cent inhibition of each compound at 12 concentrations.
Phosphorylated and Dephosphorylated Kinase Assay
Dephosphorylated conformationally inactive Abl kinase was ob-
tained by treating pure recombinant Abl with Yersinia enterocolitica
phosphatase (Calbiochem) (50 U/mg Abl) in the appropriate buffer
(100 mM Tris [pH 7.5], 150 mM NaCl, 2.5 mM EDTA, 5 mM DTT) for
30 min at 30C. The tyrosine phosphorylation status of the enzyme
was assessed by immunoblotting with anti-phosphotyrosine anti-body (4G10 clone, Upstate). After addition of Na3VO4 at a final con-
centration of 2 mM to inhibit phosphatase activity, nontreated and
dephosphorylated Abl were incubated with various concentrations
of test compounds in kinase buffer (50 mM Tris-HCl [pH 7.5], 10
mM MgCl2, 100 mM EDTA, 1 mM DTT, 0.015% Brij 35), 150 mM Abl
substrate peptide (Upstate), 100 mM ATP, and 1 mCi [g-33P]-ATP. As-
says were carried out in 96-well plates at room temperature for 30
mi, and 35 ml of the reaction mixture was transferred onto 96-well
phosphocellulose membrane plates (Millipore, Bedford, MA) previ-
ously soaked with 0.5% H3PO4 and mounted on a vacuum manifold.
Membranes were washed five times with 1.0% H3PO4, and, after ad-
dition of 10 ml/well of Microscint TM (Packard), the radioactivity
incorporated into the substrate was quantified in a Packard Top
Count. The IC50 value was calculated by linear regression analysis
of the percent inhibition curve (see the curves and the Western
blot in the Supplemental Data). The assay typically has an S/N ratio
of 30:1 or higher.
Supplemental Data
Supplemental Data include experimental details for the synthesis of
compounds, details on cocrystallization of 14 with c-Abl, and raw
data of heat maps that are included in the main text and are available
at http://www.chembiol.com/cgi/content/full/13/7/779/DC1/.
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